Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASCO & EHA 2024 AML Highlights

27 June 2024 | Virtual Meeting

Presentation summaries of key AML abstracts from ASCO & EHA 2024 featuring panel discussions with leading experts

The Post-ASCO & EHA 2024 AML Highlights was supported by Genentech. Supporters have no influence over the production of content.

Updates in transplantation Advances with menin inhibitors Optimizing risk stratification in AML Additional advances in AML management

Updates in transplantation

Firas El Chaer

Pre- allo-SCT flow cytometry testing for AML pts in first CR

Firas El Chaer University of Virginia, Charlottesville, VA, United States

Enrico Maffini

allo-SCT from haplo donors with TBI vs. chemo for AML in first remission

Enrico Maffini IRCCS AOU di Bologna, Bologna, Italy

Session 1 panel discussion

Advances with menin inhibitors

Joshua Zeidner

Beat AML: AZA + VEN + revumenib for NPM1m or KMT2A AML

Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States

Andrew Wei

JNJ-75276617 + VEN-AZA in R/R AML with KMT2A/NPM1 mut.

Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia

Naval Daver

DSP-5336 in patients with relapsed or refractory acute leukemia: Updated results from dose escalation

Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session 2 panel discussion

Optimizing risk stratification in AML

Fieke Hoff

LLS 2024 ELN-refined risk strat. in older adults w. ND AML

Fieke Hoff UT Southwestern Medical Center, Dallas, TX, United States

Dimitrios Kotsos

Adverse prognostic impact of secondary-type mutations in favorable risk AML

Dimitrios Kotsos Erasmus MC, Rotterdam, Netherlands

Session 3 panel discussion

Additional advances in AML management

Jorge Cortes

Olutasidenib for mutated IDH1 AML

Jorge Cortes UAB O’Neal Cancer Center, Birmingham, AL, United States

Uwe Platzbecker

APOLLO: ATO + ATRA vs AIDA for ND, HR-APL

Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany

Courtney DiNardo

FLAG-IDA + VEN in ND or R/R AML

Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session 4 panel discussion

Enduring Content Supported by:

Silver Supporter